local preferences, currently available test panels may include any combination of FVIII:C, VWF:Ag, VWF:RCo, VWF:CB, VWF:Act, VWF multimers, RIPA, VWF:FVIIIB, and genetic analysis. [1] [2] [3] [4] [5] [6] [7] However, the actual tests, specific test methodologies, and their combinations, as used by individual laboratories, vary widely and this will influence, according to the specific investigation, the appropriate diagnosis and typing of VWD or its exclusion. In general, the more extensive the test panel and the more thorough the investigation, the more likely the correct identification and typing of VWD. Alternatively, the use of limited test panels or poor test methodologies will compromise test accuracy and result in a high likelihood of incorrect diagnoses. This will psychologically affect individuals and compromise their therapeutic management. show moderate inter-assay or inter-laboratory variations (~10-15%), and LIA-based results tend to be slightly higher than those obtained by ELISA. 2, 6 Both ELISA and LIA methods show a lower limit of assay sensitivity of around 5-10U/dl. 8 
von Willebrand Factor: Ristocetin Co-factor
This functional assay assesses the ability of VWF to bind to GPIbα in the presence of ristocetin, and is most commonly performed as a quantitative agglutination procedure using fixed or lyophilized platelets with an aggregometer or automated coagulation analyzer. [2] [3] [4] [5] [6] This assay has the ability to preferentially identify HMW and intermediate-molecular-weight VWF, and so results tend to be lower than those of VWF:Ag when these VWF forms are lacking (i.e. types 2A
and 2B VWD). VWF:RCo is also lower than VWF:Ag when there is a specific defect in VWF binding to platelet GPIbα (i.e. with some forms of type 2M VWD). Thus, the test combination of VWF:Ag and VWF:RCo should identify and partially distinguish all types of VWD but type 2N, [2] [3] [4] [5] [6] with type 3 VWD showing an absence of VWF using both tests, type 1 VWD showing low but concordant test results with both tests, and types 2A, 2B, and most 2M cases yielding proportionally lower VWF:RCo than VWF:Ag (typically referred to as VWF functional discordance). Unfortunately, VWF:RCo has a high inter-assay or interlaboratory variability of around 30-40%, and a relatively high limit of assay sensitivity of around 15-20U/dl, which substantially limits its true utility in VWD diagnostics. 2, [4] [5] [6] 8 In practice, this means that VWF:RCo often shows both poor accuracy and precision in the diagnostically critical region of <20U/dl. VWF:CB has a moderate inter-assay or inter-laboratory variation of around 10-20%, and a similar limit of assay sensitivity to VWF:Ag. Type 3 VWD is defined where plasma VWF is 'virtually' absent. In practice, the measured levels of plasma VWF (assayed by any VWF assay) should be <5%, although this may not always be apparent with some assays due to a lower limit of assay sensitivity (see Table 1 ). 8 As plasma VWF protects and stabilizes FVIII:C, plasma levels of FVIII:C are also typically low, and usually also <5%. Type 3 VWD is a severe form of VWD, and patients may present clinically with a bleeding diathesis that resembles a combination of mucosal bleeding typical of VWD plus hemophilia A-like symptoms. The main difficulties with (mis)identification of type 3 VWD largely relate to inappropriate test panels, assay variation, and lower limit of sensitivity parameters.
Type 1 von Willebrand Disease
This is a quantitative disorder that presents with low levels of 'normalfunctioning' VWF. In practice, the presenting plasma levels of VWF would be similar, irrespective of the assay used to identify VWF (i.e.
VWF:Ag, VWF:RCo, VWF:CB, or VWF:Act; see 
Type 2A von Willebrand Disease
This defines a specific deficiency of HMW VWF, and affected individuals will therefore present with relatively lower levels of VWF:RCo and VWF:CB than VWF:Ag (see Table 1 ). In general, this functional VWF discordance is defined by ratios of VWF:RCo/VWF:Ag (RCo/Ag) and VWF:CB/VWF:Ag (CB/Ag) below ~0.7. [1] [2] [3] [4] [5] [6] Although VWF multimer analysis can confirm the loss of HMW VWF, in practice this is usually not required, and our own preference would be to perform a RIPA analysis and, if indicated, a DDAVP trial (as explained in later sections of this article).
Type 2B von Willebrand Disease
This defines individuals with hyper-adhesive VWF, who will also typically present with relatively lower levels of VWF:RCo and VWF:CB compared with VWF:Ag, or functional VWF discordance (comparable to that for 2A VWD) as defined by ratios of RCo/Ag and CB/Ag below ~0.7. Although VWF multimer analysis can also be used to confirm the loss of HMW VWF, in practice again this is usually not required, and would not enable its differentiation from type 2A VWD. The definitive phenotypic test for identifying type 2B VWD is RIPA. Type 2B VWD can be distinguished from the phenotypically similar PT-VWD using RIPA-mixing studies or by specific genetic analysis of the VWF and platelet GPIbα genes.
2,7,10,11
Type 2N von Willebrand Disease
Type 2N VWF defines dysfunctional VWF to FVIII binding and individuals will present lower relative levels of plasma FVIII:C to VWF. However, a reasonable caveat here is that it is currently impossible to truly and entirely exclude VWD using any currently applicable test panel,
given that we are unable to evaluate all possible VWF functions using current tests. Additional testing is warranted when VWF:Ag, VWF:CB, and/or FVIII:C test results are ≥75% and/or there is compelling clinical evidence of VWD-like bleeding symptoms. As shown in Figure 1 , the subtype of VWD may then be surmised by the pattern of resultant test findings, as expanded elsewhere in this article.
Evident Problems with Current Identification and Laboratory Diagnosis of von Willebrand Disease
Given appropriate selection and application of test methodologies and panels, most cases of VWD will be appropriately identified and characterized. Nevertheless, the diagnosis of VWD remains 
Towards a New Paradigm to Better Define von Willebrand Disease

Expansion to a Comprehensive Test Panel that Includes the von Willebrand Factor: Collagen Binding Assay
Due to diagnostic problems, laboratories and clinicians need additional strategies to ensure the appropriate identification of VWD.
In the 'real-world VWD testing' setting, the addition of a VWF:CB assay Unfortunately, some assay standardization concerns remain [2] [3] [4] with broadly applied and commercially available VWF:CB assays that currently prevent the more universal translation of these findings.
Use of Desmopressin Challenge to Help Identify von Willebrand Disease Subtypes
Desmopressin (DDAVP) is a non-transfusional therapy often applied to individuals with VWD that acts to release endogenous (endothelial) stores of VWF. DDAVP is particularly useful for type 1 VWD, but can also be applied to some cases of type 2 VWD. Prior to its use for therapeutic need (e.g. surgery), it is usual to assess efficacy by undertaking a DDAVP trial or challenge because responsiveness differs from individual to individual and cannot otherwise be easily predicted.
However, DDAVP responsiveness is fairly stable intra-individually, and hence a DDAVP challenge once undertaken can typically be used to predict future responsiveness from that same individual.
In addition to its therapeutic use, we and others have been interested in the potential use of DDAVP trials to help better functionally identify (using an extended test panel of FVIII:C, VWF:Ag, VWF:RCo, and VWF:CB) the VWD type of individuals, particularly those in which standard laboratory testing has failed to provide a definitive answer. 26 Thus, in a large cross-laboratory, retrospective audit of DDAVP usage and effect, we could identify patterns that we believed to be VWD subtype discriminatory (summarized in Figure 2 ). 
U S H E M A T O L O G Y
Similar observations were reported by our laboratory for type 1 VWD over 10 years ago using a small number of patients within a single institution study, 27 
Using the PFA-100 ® to Help Identify Functional von Willebrand Disease Subtypes
The above process can be extended to utilize additional test parameters, such as the PFA-100 ® (Siemens, Marburg, Germany). [35] [36] [37] [38] In brief, the PFA-100 is very sensitive to the presence of plasma VWF, and accordingly is highly sensitive to VWD. The PFA-100 gives a single endpoint value called the closure time (CT), [36] [37] [38] and individuals with VWD provide prolonged CTs, in part according to the severity and type of VWD. Our laboratory reported many years ago in a small pilot study that in type 1 VWD, DDAVP tended to normalize all of the VWF test parameters (i.e. VWF:Ag, VWF:RCo, and VWF:CB), and also tended to correct the prolonged PFA-100 CT. 35 In contrast, in type 2A VWD DDAVP tended to normalize only VWF:Ag, but not the functional VWF test parameters (i.e. VWF:RCo and VWF:CB), and also failed to correct the prolonged PFA-100 CT. The working hypothesis at that time was that normalization of the PFA-100 required normalization of functional VWF.
As an extension to the previously noted study, 26 an evaluation of the PFA-100 has also been recently undertaken in the context of DDAVP responsiveness, and in part as a follow-up to findings recently reported by others. 39, 40 It was found, using a larger number of VWD cases, that in type 1 VWD normalization of the PFA-100 CT was dependent on normalization of functional VWF, particularly that identified by the VWF:CB assay. 41 In contrast, in type 2A and 2M VWD normalization of the PFA-100 was rarely achieved, consistent with the usual finding that correction of functional VWF also failed to occur. In total, the composite data (i.e. PFA-100 CT and plasma tests for VWFAg, VWF:RCo, VWF:CB, and C. 
A: Pre-and post-desmopressin (DDAVP) values for factor VIII (FVIII):coagulant (C) and various VWF parameters. Dashed horizontal line indicates a nominal 'normal' cut-off value of 50U/dl. VWD-1s = 'severe' type 1 von Willebrand disease (VWD) patient group (baseline von
Genetic Analysis in von Willebrand Disease Diagnosis
There has been a recent explosion of genetic studies into VWD, including the previously mentioned studies into presumed type 1 VWD. 7, [13] [14] [15] [16] [17] [18] [19] The generally increased awareness of genetic testing and its availability leads to the undesirable situation that clinicians, often keen to exploit newly developed tests to assist in the diagnosis of patients under their care, will request such tests at odds to their true clinical utility and cost-effectiveness. In general, although recent studies are invaluable in terms of furthering our understanding of VWD, there are several limitations when attempting to translate research findings into diagnostically useful test strategies. 49, 50 As the VWF gene is large and complex, genetic testing for VWD is not fool-proof and is typically expensive. VWD can arise from genetic events unrelated to the VWF gene, and the expression of VWF and the clinical severity in individual patients can be influenced by several epigenetic events. Currently, most of these additional complexities remain unknown.
In type 1 VWD, the search for a causative mutation may require an exhaustive and costly analysis of the entire gene, which will remain fruitless in nearly half of test cases. A significant proportion of type 1 VWD cases where a presumptive mutation is identified will also prove to be non-causal or 'innocent' polymorphisms. Thus, the search for mutations in the vast majority of presumptive type 1 VWD investigations cannot be encouraged. The search for mutations in presumptive type 2 VWD cases will typically be more fruitful, but will still be clinically useful only in select cases where phenotypic testing has failed to provide diagnostic clarity. Excluding potential utility for pre-natal assessment in some cases of type 3 VWD, genetic investigations in type 3 VWD will otherwise also unlikely prove to be diagnostically or clinically useful. 50 Readers are also encouraged to consider the views of experts in the field, inclusive of recent guidelines. 
U S H E M A T O L O G Y
Conclusion
Historically, the diagnosis of VWD can be seen as a dynamically evolving process, 52 beginning with the global tests of coagulation, several screening tests of platelet function that included the skin-bleeding time, and progression to detection of FVIII:C and VWF:Ag. During those years, the identification of VWD remained less than optimal. The next tests of significance to emerge were those based on ristocetin (VWF:RCo and RIPA), which appeared in the 1970s. Although these permitted a sort of revolution in the investigation of VWD, diagnosis remained problematic,
given the poor reproducibility of the VWF:RCo and the poor sensitivity of RIPA for VWD. The VWF:CB was originally described in 1986, and although now over 21 years old, it still has to mature into a universally useful assay, largely because of standardization matters. 3 Interestingly, several international mutational VWD studies, which were expected to provide some definitive answers regarding phenotype-genotype correlations in VWD, have instead shown a greater complexity within VWD than previously recognized, and have also highlighted significant error rates in the diagnosis and classification of VWD among expert laboratories. 23 Errors within the real world of VWD investigation continue to cause misidentification of type 2 VWD as type 1 or 3 VWD, misidentification of type 1 VWD as type 2 or type 3 VWD, and misidentification of type 3 VWD as type 1 or 2 VWD or even hemophilia A. 12 Many of these errors occur because of assay limitations and the use of limited test panels. In particular, VWF:RCo generally shows poor inter-assay and interlaboratory precision, and also the poorest lower limit of assay sensitivity.
The test combination of FVIII:C, VWF:Ag, and VWF:RCo is the most common test panel used worldwide for the identification, diagnosis, and classification of individuals with VWD, but experience tells us that an individual will be misdiagnosed in around 25% of occasions using this test panel. 12, 23 Adding a properly optimized VWF:CB assay to this test panel will substantially reduce error rates, with remaining errors often associated with misinterpretation of laboratory data rather than actual assay failures. 12 Unfortunately, assay standardization issues prevent the proper universal worldwide adoption of VWF:CB assays, and it is doubtful that any commercial VWF:CB kit is currently truly fit for purpose. 
